Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/19074
DOI URL: http://dx.doi.org/10.21474/IJAR01/19074

RESEARCH ARTICLE

DIABETES AND PERIODONTAL DISEASE: INTERCONNECTED PATHOPHYSIOLOGY AND CLINICAL IMPLICATIONS: A COMPREHENSIVE REVIEW

Abdulrahman Abdulaziz Aldawish[1], Nawaf Mohammed Alzaben[1], Lulya Mohammed Alzain[1], Haitham Saad Alsumaihan[1], Saud Abdulaziz Alhubaish[1], Turki Saqer Almutairi[2], Dalal Munwikh Al Shammari[3], Al Hanouf Saleh AlGoudah[4], Alanoud Saleh Alturki[4] and Saleh Abdullah AlKhunein[5]

1. Prince Abdulrahman Advanced Dental Institute, Riyadh, Saudi Arabia.
2. Nursing Executive Affairs, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
3. Nursing Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
4. Department of Endocrinology and Diabetes, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
5. Department of Anesthesia, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Manuscript Info

Manuscript History
Received: 15 May 2024
Final Accepted: 18 June 2024
Published: July 2024

Key words:-
Diabetes Mellitus, Periodontal Diseases, Biomarkers, Inflammation, Interdisciplinary Care, Early Detection

Abstract

The bidirectional relationship between diabetes mellitus (DM) and periodontal disease is well-documented, with poor glycemic control exacerbating periodontal inflammation and vice versa. Novel therapies, including anti-inflammatory agents, antioxidants, and biologics, show promise in reducing systemic inflammation and improving glycemic control. Advances in identifying salivary biomarkers such as miRNAs 146a/b and 155, IL-1β, MMP8, and IL-6 have improved early detection of periodontitis in diabetic patients. Additionally, innovative imaging techniques like Raman spectroscopy and multiplex hand-held biosensors have enhanced diagnostic accuracy. Longitudinal studies and clinical trials remain essential to validate the long-term benefits and safety of new biomarkers and therapies. Recent studies highlight the importance of integrated care and interdisciplinary collaboration between dental and medical professionals to effectively manage these interrelated conditions. Future research should focus on understanding the biological pathways linking DM and periodontal disease, with a particular emphasis on the roles of inflammatory cytokines, oxidative stress, and the microbiome. Public health initiatives should aim to increase awareness of the bidirectional relationship between DM and periodontal disease through educational campaigns and community-based screening programs. Policy recommendations should encourage integrated health services and interdisciplinary training programs. The integration of artificial intelligence and machine learning in diagnostic tools offers potential for early detection and personalized treatment plans, further improving patient outcomes. Addressing these research gaps through continued investigation and technological innovation is crucial for enhancing the prevention, diagnosis, and management of diabetes and periodontal disease. These efforts will ultimately lead to better health outcomes and quality of life for affected individuals.

Corresponding Author:- Saleh Abdullah AlKhunein
Address:- Department of Anesthesia, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

……..

Introduction:-

Overview of Diabetes Mellitus and Periodontal Disease

Diabetes mellitus (DM) comprises a group of metabolic disorders characterized by persistent high blood sugar levels due to deficiencies in insulin secretion, insulin action, or both (1,2). This metabolic condition is broadly classified into two main types: Type 1 diabetes (T1D) and Type 2 diabetes (T2D), each with distinct underlying mechanisms. T1D is an autoimmune disease where the body's immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas, resulting in insufficient insulin production and necessitating lifelong insulin therapy for glucose management (3). T2D, more prevalent in occurrence, primarily involves insulin resistance, where the body's cells exhibit reduced responsiveness to insulin. Initially, the pancreas compensates by producing extra insulin, but over time, insulin secretion may decrease, leading to elevated blood sugar levels (4,5). Factors such as obesity, poor dietary habits, physical inactivity, and genetic predispositions significantly contribute to T2D development (6). Chronic hyperglycemia associated with DM leads to various complications affecting multiple organ systems. Microvascular complications include retinopathy, nephropathy, and neuropathy, while macrovascular complications encompass cardiovascular diseases (7). The management of diabetes involves a multifaceted approach including lifestyle modifications, oral hypoglycemic agents, and insulin therapy to maintain blood glucose levels within a target range and prevent complications (1,2,8).

Periodontal diseases encompass a spectrum of inflammatory conditions affecting the tissues that support the teeth, including the gums, bone, and periodontal ligament. These conditions can result in significant dental issues such as tooth loss and contribute to systemic inflammation, impacting overall health (9). Periodontitis, the most severe form of periodontal disease, is a chronic inflammatory condition triggered by microbial infection. It begins with the buildup of dental plaque along the gum line, initiating an inflammatory response. Without intervention, this inflammation can progress to periodontitis, marked by the breakdown of the periodontal ligament and bone, eventually leading to tooth loss (9).

The development of periodontitis involves a complex interplay between the oral microbiota and the immune response of the host. Imbalance in the oral microbiota, especially the proliferation of pathogenic bacteria like Porphyromonasgingivalis, disrupts the normal equilibrium of periodontal tissues. This microbial dysbiosis, coupled with the host's inflammatory reaction, results in gradual tissue destruction (10).Beyond its impact on oral health, periodontitis is associated with systemic implications. Chronic inflammation linked to periodontitis has been correlated with various systemic conditions such as cardiovascular diseases, diabetes, respiratory diseases, and adverse pregnancy outcomes. The systemic spread of inflammatory mediators and bacteria from periodontal lesions can exacerbate these conditions, highlighting the importance of managing periodontal health to mitigate broader health risks (11).Effective management of periodontal disease involves both preventive and therapeutic strategies. Preventive measures include maintaining proper oral hygiene practices and regular dental check-ups to remove dental plaque and calculus. Therapeutic interventions may involve scaling and root planing, antimicrobial treatments, and in severe cases, surgical procedures to restore periodontal structures (12).

Increasing Prevalence of Both Diseases

The prevalence of both DM and periodontal disease has been increasing globally, impacting a significant portion of the population. This trend poses serious public health challenges due to the intricate relationship between these two conditions.

The global prevalence of diabetes has seen a significant rise over the past few decades. According to the International Diabetes Federation (IDF) 10th edition (13), the number of adults aged 20-79 years with diabetes is estimated to be 537 million (10.5%) in 2021, and this number is projected to increase to 783 million (12.2%) by 2045. The prevalence is notably higher in urban areas compared to rural areas and higher in high-income countries compared to low-income countries. The rising prevalence of diabetes is attributed to factors such as aging populations, urbanization, and lifestyle changes leading to increased obesity and sedentary behaviors (14).

Periodontal disease, particularly severe periodontitis, also shows a substantial and increasing global burden. Chen et al., 2021 documented that there were approximately 1.1 billion cases of severe periodontitis worldwide, with the prevalence rate increasing by 8.44% since 1990 (15). The incidence, prevalence, and disability-adjusted life years (DALYs) due to periodontal diseases have significantly increased, with the highest burden observed in regions like

Western Sub-Saharan Africa and among populations in less developed countries(16). The increase in periodontal disease prevalence is driven by factors such as poor oral hygiene, smoking, diabetes, and inadequate access to dental care (17).

Bidirectional Relationship

Diabetes and periodontal disease share a bidirectional relationship, where each condition can adversely influence the other. Understanding this bidirectional relationship is crucial for effective management and treatment strategies (18). Diabetic patients are more susceptible to infections, including periodontal disease, due to impaired immune response and increased inflammation. Conversely, periodontal disease can adversely affect glycemic control, making diabetes management more challenging (19). Thus, effective management of both diabetes and periodontal disease requires a comprehensive approach that includes regular dental check-ups, meticulous oral hygiene, and tight glycemic control. Studies have shown that periodontal treatment can lead to significant improvements in glycemic control, reducing HbA1c levels by 0.27-0.48% after three months (20). This reduction is clinically relevant, emphasizing the role of dental care in diabetes management (21).

The integration of dental and medical care is essential for addressing the bidirectional relationship between diabetes and periodontal disease. Healthcare providers should collaborate to develop and implement joint management plans for patients with these conditions. This includes routine screening for periodontal disease in diabetic patients and vice versa, along with providing education on the importance of oral health in diabetes management (22).

Despite the well-established link between diabetes and periodontal disease, many patients lack awareness of this relationship(23). Studies indicate that less than half of people with diabetes are aware of their increased risk for periodontal disease. Moreover, healthcare providers often do not adequately inform patients about this link (24). Therefore, increasing awareness and providing education to both patients and healthcare providers is critical for improving outcomes.

The primary objective of this literature review is to summarize the current knowledge on the bidirectional relationship between DM and periodontal disease. This review aims to explore the underlying mechanisms that connect these two chronic conditions, discuss their clinical implications, and highlight effective management strategies. This will help inform future research directions and guide healthcare professionals in optimizing treatment plans for individuals affected by both diseases.

Interrelationship Between Diabetes and Periodontal Disease

Epidemiological Evidence

Numerous studies have shown a higher prevalence of periodontal disease among diabetic patients compared to non-diabetic individuals. A cross-sectional study in North India involving 427 participants revealed that over 95% of diabetic individuals exhibited some degree of periodontal destruction, with severe periodontitis prevalence increasing with poor glycemic control(25). Another study conducted in Brazil, including 117 diabetic and 158 non-diabetic patients, confirmed that periodontal disease was more prevalent and severe in diabetic patients compared to non-diabetic controls (26). Similarly, a hospital-based study in Uttarakhand, India, demonstrated a significantly higher prevalence of periodontitis in diabetic patients (97%) compared to non-diabetic controls (34%) (27). Another systematic review highlighted that the prevalence of periodontitis was significantly higher in diabetic populations, with an overall odds ratio of 2.27, indicating that diabetic individuals are more than twice as likely to suffer from periodontitis(28).

Long-term cohort studies have reinforced the bidirectional relationship between diabetes and periodontal disease. A 21-year cohort study involving nearly 9,000 individuals showed that poor periodontal health significantly increased the risk of developing diabetes (29). Another meta-analysis of 53 observational studies found that diabetic patients had significantly worse periodontal status, with increased periodontal pocket depth, attachment loss, and tooth loss compared to non-diabetic individuals (30).

Mechanistic Insights

Hyperglycemia in diabetic patients significantly contributes to periodontal inflammation. Elevated blood glucose levels enhance the formation of advanced glycation end products (AGEs), which interact with their receptor (RAGE) to amplify inflammatory responses in periodontal tissues, leading to tissue destruction(20). AGEs promote

the production of inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), which exacerbate periodontal tissue destruction(31).

The accumulation of AGEs in periodontal tissues leads to oxidative stress and increased inflammatory cytokine production, which exacerbates periodontal tissue destruction and impairs wound healing. A study highlighted that increased levels of AGEs and associated oxidative stress are significant contributors to periodontal tissue damage in diabetic patients(32).

Diabetes alters the host immune response, making individuals more susceptible to infections, including periodontal disease. The hyperglycemic environment impairs the innate immune response, leading to an exaggerated inflammatory reaction in periodontal tissues and accelerating the progression of periodontitis(19). Furthermore, diabetes increases the expression of receptor activator of nuclear factor-kappa B ligand (RANKL) in response to bacterial challenges, promoting bone resorption and periodontal tissue destruction (33).

Periodontal inflammation can adversely affect glycemic control by increasing insulin resistance. Inflammatory cytokines released from periodontal tissues can interfere with insulin signaling pathways, worsening blood glucose levels and complicating diabetes management(21,34).Clinical studies have demonstrated that treating periodontal disease can lead to significant improvements in glycemic control, evidenced by reduced HbA1c levels and improved overall metabolic control (20,21,34).

Clinical Implications

Diagnosis and Screening

Regular periodontal check-ups for diabetic patients are crucial due to the high prevalence of periodontal disease in this population. Studies have shown that diabetic patients are more susceptible to infections, including periodontal disease, due to impaired immune response and increased inflammation. Regular periodontal screenings can help in early detection and management of periodontal disease, thereby improving overall health outcomes (20). A study demonstrated that intensive periodontal treatment led to a significant reduction in HbA1c levels in diabetic patients, indicating the importance of regular periodontal screenings and treatments in managing diabetes (35). Another study suggests that gingival crevicular blood (GCB) can be utilized to evaluate blood glucose levels and glycemic control during routine dental visits, making dental offices a suitable location for diabetes screening in patients with periodontal disease (36).

Furthermore, blood glucose monitoring in periodontal patients can aid in the early detection of diabetes. Periodontal disease can be an early sign of diabetes, and dental offices can serve as effective sites for diabetes screening. A study highlighted that a significant prevalence of undiagnosed diabetes and pre-diabetes was found in patients with periodontal disease (37). Screening for diabetes in dental settings using validated methods like glycated hemoglobin (HbA1c) testing can identify individuals at risk and improve management of both conditions(37).

Management Strategies

Glycemic Control and Periodontal Health

Glycemic control and periodontal health are deeply intertwined, with each condition influencing the other. Maintaining optimal glycemic control is crucial for preventing and managing periodontal disease, and effective periodontal treatment can significantly improve glycemic control in diabetic patients. Integrated management strategies that address both glycemic control and periodontal health are essential for improving patient outcomes. Effective periodontal treatment has been shown to improve glycemic control in diabetic patients. A 12-month study demonstrated that intensive periodontal treatment significantly reduced HbA1c levels in patients with T2D and moderate-to-severe periodontitis (35). A study analyzing data from the National Health and Nutrition Examination Survey (NHANES) found that individuals with periodontitis had higher mean glycohemoglobin levels compared to those without periodontitis, further illustrating the adverse impact of periodontal disease on glycemic control (38).

Periodontal Treatment Modalities

Non-surgical periodontal treatment, such as scaling and root planing (SRP), is effective in reducing periodontal inflammation and improving glycemic control. A systematic review and meta-analysis of randomized controlled trials (RCTs) demonstrated that SRP significantly reduces glycated hemoglobin (HbA1c) levels in patients with T2DM. The review reported a reduction in HbA1c levels by 0.29% at 3-4 months and 0.02% at 6 months post-

treatment (34,39). Another study corroborated these findings, showing significant improvements in periodontal health and glycemic control following non-surgical periodontal treatment (40).

The use of adjunctive antimicrobial therapy alongside SRP can further enhance treatment outcomes. For example, the addition of subgingival povidone-iodine irrigation to SRP was shown to significantly improve periodontal health and reduce HbA1c levels in poorly controlled diabetic patients (41).

In cases of advanced periodontitis, surgical interventions may be necessary. These include flap surgery to remove deep-seated plaque and tartar, bone grafts to regenerate lost bone tissue, and soft tissue grafts to cover exposed roots. Surgical treatments, combined with meticulous post-operative care, have been shown to provide significant improvements in both periodontal and glycemic outcomes (42).

Interdisciplinary Approach

Collaboration between dentists, endocrinologists, and other healthcare providers is vital for comprehensive care of patients with diabetes and periodontal disease. An interdisciplinary approach ensures that both conditions are managed effectively, with coordinated efforts to address the underlying inflammation and metabolic dysregulation. This collaboration can lead to better patient education, improved treatment adherence, and overall enhanced health outcomes (43–45).

Patient Education and Lifestyle Modifications

Educating patients on proper oral hygiene practices is crucial in managing both diabetes and periodontal disease. Good oral hygiene, including regular brushing, flossing, and professional cleanings, can help reduce periodontal inflammation and improve glycemic control. Patients should be informed about the link between oral health and diabetes and encouraged to maintain regular dental visits(46).Nutritional advice plays a significant role in managing both diabetes and periodontal health. A balanced diet that controls blood sugar levels can help reduce the risk of periodontal disease and improve overall health. Patients should be advised to avoid foods high in sugar and processed carbohydrates, which can exacerbate both conditions. Instead, they should focus on a diet rich in vegetables, fruits, lean proteins, and whole grains(47).

Recent Advances and Emerging Therapies

The management of periodontal disease in patients with diabetes has seen significant advancements in recent years. These advances are focused on enhancing both glycemic control and periodontal health through various pharmacological interventions and innovative treatment modalities. A flowchart that outlines the clinical management strategies is shown in **Table 1**, highlighting the significance of integrated care and regular follow-ups to ensure effective management of diabetes and periodontal disease.

Pharmacological Interventions

Anti-inflammatory Agents

Inflammation is a key factor in both diabetes and periodontal disease, driving the progression of both conditions. Recent research has explored the use of anti-inflammatory agents to manage periodontal inflammation and improve glycemic control. Another promising area of research involves the use of non-steroidal anti-inflammatory drugs (NSAIDs). Studies have shown that NSAIDs can reduce periodontal inflammation by inhibiting cyclooxygenase (COX) enzymes, which are involved in the inflammatory process. Although the long-term use of NSAIDs is limited by potential side effects, short-term application as an adjunct to periodontal therapy may offer benefits in reducing periodontal inflammation and improving glycemic control (Stoica et al., 2022).

Sulfonylureas

Traditionally used as oral hypoglycemic agents, sulfonylureas have shown potential benefits beyond glycemic control due to their anti-inflammatory properties. Studies have indicated that sulfonylureas can mitigate inflammation and bone loss associated with periodontitis-diabetes comorbidity, reducing inflammatory markers and improving periodontal health (48).

Colchicine

Known primarily for treating gout, colchicine has emerged as a promising anti-inflammatory agent in periodontal therapy. A pilot randomized controlled trial is investigating the effects of periodontal treatment combined with colchicine on inflammation in patients with periodontitis and cardiovascular disease. Preliminary results suggest that

this combination can significantly reduce systemic inflammation, beneficial for both periodontal and cardiovascular health(49).

Non-steroidal Anti-inflammatory Drugs (NSAIDs)
NSAIDs have been long recognized for their ability to reduce periodontal inflammation. However, their long-term use is limited by gastrointestinal side effects. Recent developments in NSAID formulations, such as hydrogen sulfide-releasing NSAIDs like ATB-352, have shown promising results. These derivatives exhibit reduced gastrointestinal toxicity while effectively diminishing periodontal inflammation and bone resorption (50).

Metformin
Traditionally used for diabetes management, metformin has demonstrated significant anti-inflammatory effects beneficial for periodontal health. It has been shown to ameliorate periodontal infection and tissue destruction in diabetic periodontitis by inhibiting specific inflammatory pathways, including the NIMA-related kinase 7 (Nek7)/NOD-like receptor family pyrin domain containing 3 (NLRP3) pathway (51).

Chemically Modified Tetracyclines (CMTs)
These non-antibacterial formulations of tetracyclines have been developed to exploit their anti-collagenase properties without the antimicrobial effects. Subantimicrobial-dose doxycycline (SDD) has been effective in reducing periodontal inflammation and systemic complications related to diabetes. It inhibits matrix metalloproteinases (MMPs) and reduces collagen degradation, thus providing a valuable adjunctive therapy for managing periodontal disease in diabetic patients (52).

IL-1 ReceptorAntagonists (IL-1ra)
Recent studies have investigated the use of IL-1 receptor antagonists to mitigate periodontal inflammation in diabetic patients. A study involving the development of a thermosensitive hydrogel loaded with IL-1ra demonstrated significant anti-inflammatory effects in high-sugar environments. The hydrogel was able to reduce the expression of inflammatory cytokines such as IL-1β, IL-6, and TNF-α, as well as inhibit periodontal inflammation and alveolar bone absorption in diabetic rats(53).

Sub-antimicrobial Dose Doxycycline (SDD)
SDD works by inhibiting matrix metalloproteinases (MMPs), which are enzymes involved in tissue destruction and inflammation. Several studies have demonstrated the efficacy of SDD in reducing periodontal inflammation and improving glycemic control.A randomized, double-blind, placebo-controlled study examined the effectiveness of SDD in combination with nonsurgical periodontal therapy (SRP) compared to SRP alone. The study found that SDD significantly improved clinical periodontal parameters and reduced levels of MMP-8 and MMP-9 in gingival crevicular fluid, indicating reduced tissue catabolism and inflammation (54). Another study on hypertensive rats with ligature-induced periodontitis showed that SDD administration resulted in reduced systolic blood pressure, decreased bone and attachment loss, and a downregulation of inflammatory gene profiles (55).

Antioxidant Agents
Oxidative stress plays a crucial role in the pathogenesis of both diabetes and periodontal disease. Antioxidants have been studied for their potential to mitigate oxidative stress and improve clinical outcomes. Research has demonstrated that antioxidantscan reduce oxidative stress markers and improve periodontal health.

Coenzyme Q10 (CoQ10)
CoQ10 has been extensively studied for its antioxidant and anti-inflammatory properties in managing periodontal disease, particularly in diabetic patients. CoQ10 serves as an endogenous antioxidant and has been shown to reduce periodontal inflammation and improve clinical parameters. A study found that CoQ10 supplementation as an adjunct to SRP significantly reduced gingival inflammation and periodontal tissue destruction in patients with chronic periodontitis and T2D (56). Research on diabetic hypercholesterolemia-induced periodontitis in rats demonstrated that CoQ10 supplementation improved lipid profiles and reduced periodontal inflammation, highlighting its potential therapeutic benefits (57). An RCT evaluating CoQ10 along with SRP in controlled diabetic patients showed significant improvements in periodontal and gingival indices, suggesting that CoQ10 may accelerate the treatment process and reduce pocket depth (58). Another study demonstrated that subgingival application of CoQ10 in smokers with chronic periodontitis resulted in significant improvements in clinical periodontal parameters, indicating its beneficial effects when used as an adjunct to SRP (59). An innovative study on CoQ10-loaded

nanomicelles found that this formulation, when used with SRP, significantly managed periodontal parameters and enhanced antioxidant activity, suggesting that nanotechnology could improve the therapeutic efficacy of CoQ10 (60).

Curcumin and Rutin
Curcumin and rutin are antioxidants that have shown promising results in reducing oxidative stress in diabetic rats with periodontitis. A study found that these antioxidants significantly reduced levels of malondialdehyde (MDA) and increased the antioxidant capacity in both blood and gingival tissue, indicating their potential in managing oxidative stress associated with periodontal disease and diabetes (61).

Baicalein
Baicalein, a flavonoid, has demonstrated antioxidant effects through the Nrf2 signaling pathway. This pathway is crucial for cellular defense against oxidative stress. In a study on diabetic rats with periodontitis, baicalein reduced oxidative stress markers and periodontal tissue destruction, highlighting its potential therapeutic properties (62).

Melatonin
Melatonin has been extensively studied for its antioxidant and anti-inflammatory properties. A double-blind, placebo-controlled trial demonstrated that melatonin supplementation, combined with non-surgical periodontal therapy (NSPT), significantly improved inflammatory and antioxidant parameters in patients with T2D and periodontal disease. This included reductions in serum levels of MDA and interleukin-1β (IL-1β) and increases in total antioxidant capacity (TAC), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) (54).

Resveratrol
Resveratrol, a polyphenolic compound, has shown potential in reducing oxidative stress and inflammation. A study investigating its effects on patients with type 2 diabetes and chronic periodontitis found that resveratrol supplementation significantly reduced serum levels of interleukin-6 (IL-6), a marker of inflammation, although it did not significantly change TNF-α, TAC, and clinical attachment loss (CAL) (63).

Vitamin C and E
These antioxidants have been studied for their role in periodontal health. A systematic review indicated that vitamin E, in particular, showed significant improvements in periodontal parameters when used as an adjunct to conventional periodontal therapy. However, the evidence for vitamin C was less conclusive(64).

Omega-3 Fatty Acids
Known for their anti-inflammatory properties, omega-3 fatty acids have shown promise as adjuncts to non-surgical periodontal therapy (NSPT). Studies have demonstrated that omega-3 fatty acids, when used alongside NSPT, significantly improve periodontal outcomes and glycemic control in patients with diabetes and chronic periodontitis (65).

Carvacrol and Magnolol
Carvacrol, a phenolic monoterpenoid, and magnolol, a polyphenolic compound, have been identified for their anti-inflammatory and antioxidant properties. A review highlighted that these compounds can reduce inflammation, oxidative stress, and bone loss associated with periodontitis and diabetes. Their multifunctional roles suggest potential therapeutic applications in managing both conditions (66).

p-Coumaric Acid (p-CA)
p-Coumaric acid is another antioxidant that has shown protective effects against diabetes-associated periodontal destruction. A study on diabetic mice demonstrated that oral supplementation with p-CA reduced inflammation, oxidative stress, and osteoclastic activation in periodontal tissues(67).

The abovementioned pharmacological interventions highlight the potential of anti-inflammatory and antioxidant agents in managing the complex interplay between diabetes and periodontal disease. Continued research and clinical trials are essential to further understand their efficacy and optimize treatment protocols for these interconnected conditions.

Technological Innovations

Biomarkers for Early Detection

Recent advancements in identifying biomarkers have significantly improved the early detection of periodontal disease, particularly in patients with diabetes(31,68). The use of biomarkers such as microRNAs (miRNAs) has shown great potential(69). A study by Al-Rawi et al. (2020) identified miRNAs 146a/b and 155 in saliva as reliable, non-invasive diagnostic biomarkers for periodontitis in diabetic and non-diabetic patients. These miRNAs were found to be elevated in patients with periodontitis and diabetes, making them valuable for early diagnosis (70).Another significant development is the identification of salivary molecular biomarkers such as IL-1β, MMP8, IL-6, and haemoglobin. A systematic review and meta-analysis by Arias-Bujanda et al. (2019) found that these biomarkers have good diagnostic capacity for detecting periodontitis in systemically healthy individuals, with IL-1β and MMP8 showing the highest diagnostic accuracy (71).The development of spectroscopic probes for chairside identification of specific biomarkers like MMP-8 in diabetic patients has also been noteworthy. This approach allows for the early detection of periodontal disease, enhancing the ability to monitor and manage the condition effectively (68,72).

Advances in Imaging and Diagnostic Tools

Advances in imaging and diagnostic tools have also contributed significantly to the early detection and management of periodontal disease. Innovative technologies such as Raman spectroscopy and magnetic nanoparticle biosensors have improved the accuracy and sensitivity of periodontal diagnostics.Raman spectroscopy, coupled with the use of MMP-8 immunoassays, has been employed to detect periodontal disease in diabetic patients at an early stage. This technique allows for non-invasive, real-time monitoring of periodontal health, providing valuable insights into disease progression and treatment efficacy (72).The development of multiplex hand-held colorimetric diagnostic biosensors has also shown promise. These biosensors use specific protease probes to detect biomarkers such as human neutrophil elastase (HNE) and cathepsin-G in saliva, offering a rapid, point-of-care diagnostic tool for periodontitis (73).

Future Research Directions

Despite the advancements in understanding the relationship between periodontal disease and DM, several research areas remain underexplored and require further investigation to develop more effective management and treatment strategies. While studies have demonstrated that periodontal treatment can improve glycemic control, the long-term effects remain unclear. Extensive clinical trials and longitudinal studies are essential to validate the efficacy of new biomarkers and diagnostic tools. These studies will provide robust data on the long-term benefits and potential risks associated with emerging therapies and technologies, guiding clinical practice and policy development. The integration of advanced technologies such as artificial intelligence (AI) and machine learning in diagnostic tools is a promising area. These technologies can analyze large datasets to identify patterns and predict disease progression, improving early detection and personalized treatment plans. For instance, the use of machine learning algorithms to analyze oral microbiome profiles has shown potential in predicting periodontitis, providing a non-invasive diagnostic approach (74). Additionally, identifying reliable biomarkers for the early detection of periodontal disease in diabetic patients is crucial. While several salivary biomarkers, such as IL-1β, MMP8, and IL-6, have shown promise, more research is needed to validate their diagnostic accuracy and clinical utility. Studies should also explore new biomarkers that can provide early and precise detection of periodontal disease and its progression(71).

Understanding the mechanistic links between periodontal disease and diabetes is essential for developing targeted therapies. Future research should focus on elucidating the biological pathways that connect these conditions, such as the roles of inflammatory cytokines, oxidative stress, and the microbiome. Mechanistic studies can provide insights into how periodontal inflammation affects systemic health and glycemic control(20). Moreover, evaluating the effectiveness of novel therapies, including anti-inflammatory agents, antioxidants, and biologics, in managing periodontal disease and improving glycemic control in diabetic patients is another critical area. Research should investigate the long-term safety and efficacy of these therapies and their potential to reduce the systemic inflammatory burden(50).

Future studies should emphasize the importance of interdisciplinary approaches in managing patients with periodontal disease and diabetes. Collaboration between dentists, endocrinologists, and other healthcare professionals is crucial for comprehensive care. Research should explore the benefits of integrated care models and how they can improve patient outcomes(75,76). On the other hand, investigating the impact of patient education and behavior modification programs on periodontal and glycemic health is essential. Studies should assess the

effectiveness of different educational interventions and strategies to promote oral hygiene, regular dental check-ups, and lifestyle changes in diabetic patients (18).

Table 1:- Flowchart for Clinical Management Strategies.

Steps	Clinical Management Strategies
Step 1	**Patient Presentation** • Patient presents with either diabetes mellitus (DM) or periodontal disease (PD)
Step 2	**Initial Assessment** • For diabetic patients: o Conduct a comprehensive medical history review o Measure HbA1c levels and assess glycemic control o Perform a periodontal examination • For periodontal patients: o Conduct a comprehensive dental history review o Assess periodontal status (pocket depth, bleeding on probing, clinical attachment loss) o Screen for diabetes (fasting blood glucose, HbA1c)
Step 3	**Diagnosis** • Confirm diagnosis of PD and/or DM o Use biomarkers (e.g., IL-1β, MMP8, miRNAs) for early detection o Utilize imaging tools (e.g., Raman spectroscopy, colorimetric biosensors) for accurate diagnosis
Step 4	**Treatment Planning** • Integrated care approach: o Develop a personalized treatment plan involving both dental and medical professionals o Schedule interdisciplinary case meetings if necessary
Step 5	**Treatment Implementation** • For diabetic patients with PD: o Initiate non-surgical periodontal therapy (scaling and root planing) o Consider adjunctive therapies (e.g., anti-inflammatory medications) o Monitor and adjust diabetes medication as needed • For periodontal patients with DM: o Educate on oral hygiene practices and the importance of glycemic control o Prescribe systemic or local antimicrobials if necessary o Address lifestyle factors (e.g., smoking cessation, diet modification)
Step 6	**Monitoring and Follow-up** • Regular follow-up appointments: o For periodontal health: schedule maintenance visits every 3-6 months o For diabetes management: monitor HbA1c and other relevant biomarkers periodically • Evaluate treatment outcomes: o Reassess periodontal status and glycemic control o Adjust treatment plan based on progress and any complications
Step 7	**Long-term Maintenance** • Ensure ongoing interdisciplinary communication between dental and medical teams • Encourage patient adherence to treatment plans and lifestyle modifications • Update care plans based on latest research and technological advancements

Conclusion:-

The relationship between DM and periodontal disease is well-established and bidirectional. Poor glycemic control exacerbates periodontal inflammation, while periodontal disease can negatively impact blood glucose levels, creating a vicious cycle. Studies have consistently shown that diabetic patients are more susceptible to periodontal disease and that effective management of one condition positively affects the other. This interconnected nature of diabetes and periodontal disease necessitates a coordinated approach to care. Interdisciplinary collaboration between dental and medical professionals is crucial for comprehensive patient management. This integrated care model ensures that both conditions are addressed simultaneously, improving overall health outcomes and reducing systemic inflammation.

Healthcare providers should adopt a holistic approach when treating patients with either diabetes or periodontal disease. Regular periodontal screenings should be part of the routine care for diabetic patients, and vice versa. Utilizing advanced diagnostic tools and biomarkers can aid in early detection and better management of these conditions. Practitioners should also educate patients about the importance of maintaining good oral hygiene and controlling blood glucose levels to prevent complications.

Public health strategies should focus on increasing awareness about the bidirectional relationship between diabetes and periodontal disease. Initiatives could include educational campaigns, community-based screening programs, and integrated health services that combine dental and medical care. Policy recommendations should advocate for training programs that encourage collaboration between dentists and endocrinologists, ensuring that healthcare providers are well-equipped to manage these interconnected conditions. The future of managing diabetes and periodontal disease lies in continued research and technological advancements. Future studies should focus on long-term clinical trials and the development of novel therapies that address both conditions simultaneously. Integrating AI and machine learning into diagnostic tools can enhance early detection and personalized treatment plans. By addressing the current gaps in research and fostering interdisciplinary collaboration, we can improve patient outcomes and quality of life for those affected by diabetes and periodontal disease.

References:-

1. Ebada MA, Fayed N, Fayed L, Alkanj S, Abdelkarim A, Farwati H, et al. Efficacy of Alpha-lipoic Acid in The Management of Diabetes Mellitus: A Systematic Review and Meta-analysis. Iran J Pharm Res IJPR. 2019;18(4):2144–56.
2. Abdelhaleem IA, Salamah HM, Alsabbagh FA, Eid AM, Hussien HM, Mohamed NI, et al. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Vol. 15, Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2021.
3. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective. Vol. 92, Postgraduate Medical Journal. 2016. p. 63–9.
4. Li APZ, Kariyawasam D. Type 2 Diabetes Mellitus. In: Comprehensive Pharmacology. 2022. p. 225–43.
5. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug;21(17):6275.
6. Rachdaoui N. Insulin: The friend and the foe in the development of type 2 diabetes mellitus. Vol. 21, International Journal of Molecular Sciences. 2020. p. 1–21.
7. Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020;10(04):174–88.
8. Yash Sahebrao Chaudhari, Yash Sahebrao Chaudhari, Srushti Sunil Bhujbal, Vidya Ashok Walunj, Neha Satish Bhor, Rutuja Dattatraya Vyavhare. Diabetes Mellitus: A Review. Int J Adv Res Sci Commun Technol. 2023;16–22.
9. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. Vol. 3, Nature Reviews Disease Primers. 2017.
10. How KY, Song KP, Chan KG. Porphyromonas gingivalis: An overview of periodontopathic pathogen below the gum line. Vol. 7, Frontiers in Microbiology. 2016.
11. Martínez-García M, Hernández-Lemus E. Periodontal Inflammation and Systemic Diseases: An Overview. Vol. 12, Frontiers in Physiology. 2021.
12. Könönen E, Gursoy M, Gursoy UK. Periodontitis: A multifaceted disease of tooth-supporting tissues. Vol. 8, Journal of Clinical Medicine. 2019.
13. Federation ID. IDF Diabetes Atlas Tenth edition 2021. International Diabetes Federation. 2021. p. 176.
14. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.
15. Chen MX, Zhong YJ, Dong QQ, Wong HM, Wen YF. Global, regional, and national burden of severe periodontitis, 1990–2019: An analysis of the Global Burden of Disease Study 2019. J Clin Periodontol. 2021;48(9):1165–88.
16. Wu L, Zhang SQ, Zhao L, Ren ZH, Hu CY. Global, regional, and national burden of periodontitis from 1990 to 2019: Results from the Global Burden of Disease study 2019. J Periodontol. 2022;93(10):1445–54.
17. Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim). 2017;1(2):72–80.

18. Siddiqi A, Zafar S, Sharma A, Quaranta A. Awareness of Diabetic Patients Regarding the Bidirectional Association between Periodontal Disease and Diabetes Mellitus: A Public Oral Health Concern. J Contemp Dent Pract. 2020;21(11):1270–4.
19. Genco RJ, Graziani F, Hasturk H. Effects of periodontal disease on glycemic control, complications, and incidence of diabetes mellitus. Vol. 83, Periodontology 2000. 2020. p. 59–65.
20. Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT, Graziani F, et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J Clin Periodontol. 2018;45(2):138–49.
21. Preshaw PM, Bissett SM. Periodontitis and diabetes. Br Dent J. 2019;227(7):577–84.
22. Jain A, Chawla M, Kumar A, Chawla R, Grover V, Ghosh S, et al. Management of periodontal disease in patients with diabetes- good clinical practice guidelines: A joint statement by Indian Society of Periodontology and Research Society for the Study of Diabetes in India. J Indian Soc Periodontol. 2020;24(6):498–524.
23. Siddiqi A, Zafar S, Sharma A, Quaranta A. Diabetes mellitus and periodontal disease: The call for interprofessional education and interprofessional collaborative care - A systematic review of the literature. Vol. 36, Journal of Interprofessional Care. 2022. p. 93–101.
24. Maia MB, Souza JGS, Bertolini M, Costa RC, Costa GS, Torres S de AS, et al. Knowledge of bidirectional relationship between diabetes and periodontal disease among diabetes patients: A systematic review. Int J Dent Hyg. 2023;21(1):28–40.
25. Singh M, Bains V, Jhingran R, Srivastava R, Madan R, Maurya S, et al. Prevalence of periodontal disease in type 2 diabetes mellitus patients: A cross-sectional study. Contemp Clin Dent. 2019;10(2):349–57.
26. Trentin MS, de Carli JP, Ferreira M de C, Gambin DJ, da Silva SO, Lisboa H. Prevalence and severity of periodontal disease in type 2 diabetes mellitus patients: A cross-sectional study. Biosci J. 2018;34(4):1114–23.
27. Shah DA. Periodontal Disease as a Complication in Type 2 Diabetes Mellitus– A Hospital Based Study in Uttarakhand, India. J Med Sci Clin Res [Internet]. 2016 Apr 17; Available from: http://jmscr.igmpublication.org/v4-i4/31 jmscr.pdf
28. Ziukaite L, Slot DE, Van der Weijden FA. Prevalence of diabetes mellitus in people clinically diagnosed with periodontitis: A systematic review and meta-analysis of epidemiologic studies. Vol. 45, Journal of Clinical Periodontology. 2018. p. 650–62.
29. Holmlund A, Lind L. Periodontal disease and a poor response to periodontal treatment were associated with an increased risk of incident diabetes: A longitudinal cohort study in Sweden. J Clin Periodontol. 2021;48(12):1605–12.
30. Wu CZ, Yuan YH, Liu HH, Li SS, Zhang BW, Chen W, et al. Epidemiologic relationship between periodontitis and type 2 diabetes mellitus. BMC Oral Health. 2020;20(1).
31. Sczepanik FSC, Grossi ML, Casati M, Goldberg M, Glogauer M, Fine N, et al. Periodontitis is an inflammatory disease of oxidative stress: We should treat it that way. Vol. 84, Periodontology 2000. 2020. p. 45–68.
32. Xiao E, Wu Y, Graves DT. Impact of Diabetes on Periodontal Disease. In: Diabetic Bone Disease [Internet]. Cham: Springer International Publishing; 2016. p. 95–112. Available from: http://link.springer.com/10.1007/978-3-319-16402-1_5
33. Graves DT, Ding Z, Yang Y. The impact of diabetes on periodontal diseases. Vol. 82, Periodontology 2000. 2020. p. 214–24.
34. Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, et al. Periodontitis and diabetes: A two-way relationship. Vol. 55, Diabetologia. 2012. p. 21–31.
35. D'Aiuto F, Gkranias N, Bhowruth D, Khan T, Orlandi M, Suvan J, et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. 2018;6(12):954–65.
36. Teeuw WJ, Kosho MXF, Poland DCW, Gerdes VEA, Loos BG. Periodontitis as a possible early sign of diabetes mellitus. BMJ Open Diabetes Res Care. 2017;5(1).
37. Su N, Teeuw WJ, Loos BG, Kosho MXF, van der Heijden GJMG. Development and validation of a screening model for diabetes mellitus in patients with periodontitis in dental settings. Clin Oral Investig. 2020;24(11):4089–100.
38. Garcia D, Tarima S, Okunseri C. Periodontitis and Glycemic Control in Diabetes: NHANES 2009 to 2012. J Periodontol. 2015;86(4):499–506.
39. Simpson TC, Clarkson JE, Worthington H V., MacDonald L, Weldon JC, Needleman I, et al. Treatment of periodontitis for glycaemic control in people with diabetes mellitus. Vol. 2022, Cochrane Database of Systematic Reviews. 2022.

40. Nguyen VM, Ta AT, Nguyen TTT. Assess the effect of periodontal treatment on glycemic control in type 2 diabetes patients. J Med Pharm. 2019;7–14.
41. Tsobgny-Tsague NF, Lontchi-Yimagou E, Nana ARN, Tankeu AT, Katte JC, Dehayem MY, et al. Effects of nonsurgical periodontal treatment on glycated haemoglobin on type 2 diabetes patients (PARODIA 1 study): A randomized controlled trial in a sub-Saharan Africa population. BMC Oral Health. 2018;18(1).
42. Santonocito S, Polizzi A, Marchetti E, Dalessandri D, Migliorati M, Lupi SM, et al. Impact of Periodontitis on Glycemic Control and Metabolic Status in Diabetes Patients: Current Knowledge on Early Disease Markers and Therapeutic Perspectives. Vol. 2022, Mediators of Inflammation. 2022.
43. Petrova TG, Borodina NB, Rymar SD, Rymar OD. The interaction of the dentist with an endocrinologist – a team approach in the treatment of inflammatory periodontal diseases in patients with type 2 diabetes mellitus (literature review). Periodontology. 2019;24(2):140–4.
44. Sangappa S, Babu H, Chacko S, Jithendra A, Kenkere Ms. Value of interdisciplinary approach in the management of type 2 diabetes mellitus, periodontitis, and tooth loss: Narrative review. Indian J Heal Sci Biomed Res. 2023;16(1):30.
45. Darling-Fisher CS, Kanjirath PP, Peters MC, Borgnakke WS. Oral Health: An Untapped Resource in Managing Glycemic Control in Diabetes and Promoting Overall Health. J Nurse Pract. 2015;11(9):889–96.
46. Verhulst MJL, Teeuw WJ, Gerdes VEA, Loos BG. Implementation of an oral care protocol for primary diabetes care: A pilot cluster-randomized controlled trial. Ann Fam Med. 2021;19(3):197–206.
47. Ryan ME, Raja V. Diet, Obesity, Diabetes, and Periodontitis: a Syndemic Approach to Management. Vol. 3, Current Oral Health Reports. 2016. p. 14–27.
48. Yang L, Ge Q, Ye Z, Wang L, Wang L, Mashrah MA, et al. Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone. Vol. 12, Frontiers in Pharmacology. 2021.
49. King S, Church L, Garde S, Chow CK, Akhter R, Eberhard J. Targeting the reduction of inflammatory risk associated with cardiovascular disease by treating periodontitis either alone or in combination with a systemic anti-inflammatory agent: protocol for a pilot, parallel group, randomised controlled trial. BMJ Open. 2022;12(11).
50. Gugliandolo E, Fusco R, D'Amico R, Militi A, Oteri G, Wallace JL, et al. Anti-inflammatory effect of ATB-352, a H2S −releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats. Pharmacol Res. 2018;132:220–31.
51. Zhou X, Zhang P, Wang Q, Ji N, Xia S, Ding Y, et al. Metformin ameliorates experimental diabetic periodontitis independently of mammalian target of rapamycin (mTOR) inhibition by reducing NIMA-related kinase 7 (Nek7) expression. J Periodontol. 2019;90(9):1032–42.
52. Golub LM, Elburki MS, Walker C, Ryan M, Sorsa T, Tenenbaum H, et al. Non-antibacterial tetracycline formulations: Host-modulators in the treatment of periodontitis and relevant systemic diseases. Vol. 66, International Dental Journal. 2016. p. 127–35.
53. Liu Y, Liu C, Wang C, Zhang Q, Qu X, Liang C, et al. Treatment of Periodontal Inflammation in Diabetic Rats with IL-1ra Thermosensitive Hydrogel. Int J Mol Sci. 2022;23(22).
54. Javid AZ, Hosseini SA, Gholinezhad H, Moradi L, Haghighi-Zadeh MH, Bazyar H. Antioxidant and anti-inflammatory properties of melatonin in patients with type 2 diabetes mellitus with periodontal disease under non-surgical periodontal therapy: A double-blind, placebo-controlled trial. Diabetes, Metab Syndr Obes. 2020;13:753–61.
55. Vieira GHA, Messora MR, Moura JMT, Fernandes PG, Furlaneto FAC, Palioto DB, et al. Sub-antimicrobial doses of doxycycline decreased bone loss related to ligature-induced periodontitis in hypertensive rats. Arch Oral Biol. 2019;101:77–84.
56. Shoukheba M, El- Kholy S. Coenzyme Q10 Food Supplement on the Treatment of Chronic Periodontitis in Patients with Type II Diabetes Mellitus: A Randomized Control Study. Egypt Dent J. 2019;65(1):253–61.
57. Saryono S, Devinta H, Widodo AHB, Hidayat AI. Coenzyme q10 is potentially usedto improve lipid profile in diabetic hypercholesterolemia-induced periodontitis in the coastal area. In: E3S Web of Conferences. 2018.
58. Ghasemi S, Torab Z, Shirmohammadi A, Babaloo A, Johari R, Farhadi F, et al. Evaluation of the effect of coenzyme Q10 supplementation along with scaling and root planing (SRP) on periodontal and gingival indices in controlled diabetic patients. J Adv Periodontol Implant Dent. 2022;14(1):32–7.
59. Raut CP, Sethi KS, Kohale B, Mamajiwala A, Warang A. Subgingivally delivered coenzyme Q10 in the treatment of chronic periodontitis among smokers: A randomized, controlled clinical study. J Oral Biol Craniofacial Res. 2019;9(2):204–8.

60. Shaheen MA, Elmeadawy SH, Bazeed FB, Anees MM, Saleh NM. Innovative coenzyme Q10-loaded nanoformulation as an adjunct approach for the management of moderate periodontitis: preparation, evaluation, and clinical study. Drug Deliv Transl Res. 2020;10(2):548–64.
61. Iova GM, Calniceanu H, Popa A, Szuhanek CA, Marcu O, Ciavoi G, et al. The antioxidant effect of curcumin and rutin on oxidative stress biomarkers in experimentally induced periodontitis in hyperglycemicwistar rats. Molecules. 2021;26(5).
62. Zhu C, Zhao Y, Wu X, Qiang C, Liu J, Shi J, et al. The therapeutic role of baicalein in combating experimental periodontitis with diabetes via Nrf2 antioxidant signaling pathway. J Periodontal Res. 2020;55(3):381–91.
63. Javid AZ, Hormoznejad R, Yousefimanesh H allah, Haghighi-zadeh MH, Zakerkish M. Impact of resveratrol supplementation on inflammatory, antioxidant, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Diabetes Metab Syndr Clin Res Rev. 2019;13(4):2769–74.
64. Gomes Muniz FWM, Nogueira SB, Vasconcelos Mendes FL, Rösing CK, Mendes Moreira MMS, De Andrade GM, et al. The impact of antioxidant agents complimentary to periodontal therapy on oxidative stress and periodontal outcomes: A systematic review. Vol. 60, Archives of Oral Biology. 2015. p. 1203–14.
65. Rampally P, Koduganti R, Ganapathi S, Panthula V, Surya P. Comparison of effectiveness of low-dose aspirin versus omega-3 fatty acids as adjuvants to nonsurgical periodontal therapy in Type II diabetic patients with chronic periodontitis. J Indian Soc Periodontol. 2019;23(3):249–56.
66. Cicalău GIP, Babes PA, Calniceanu H, Popa A, Ciavoi G, Iova GM, et al. Anti-inflammatory and antioxidant properties of carvacrol and magnolol, in periodontal disease and diabetes mellitus. Vol. 26, Molecules. 2021.
67. Bhattarai G, Min CK, Jeon YM, Bashyal R, Poudel SB, Kook SH, et al. Oral supplementation with p-coumaric acid protects mice against diabetes-associated spontaneous destruction of periodontal tissue. J Periodontal Res. 2019;54(6):690–701.
68. Sedghi LM, Bacino M, Kapila YL. Periodontal Disease: The Good, The Bad, and The Unknown. Vol. 11, Frontiers in Cellular and Infection Microbiology. 2021.
69. Ebada MA, Mostafa A, Gadallah AHA, Alkanj S, Alghamdi BS, Ashraf GM, et al. Potential Regulation of miRNA-29 and miRNA-9 by Estrogens in Neurodegenerative Disorders: An Insightful Perspective. Vol. 13, Brain Sciences. 2023.
70. Al-Rawi NH, Al-Marzooq F, Al-Nuaimi AS, Hachim MY, Hamoudi R. Salivary microrna 155, 146a/b and 203: A pilot study for potentially non-invasive diagnostic biomarkers of periodontitis and diabetes mellitus. PLoS One. 2020;15(8 August).
71. Arias-Bujanda N, Regueira-Iglesias A, Balsa-Castro C, Nibali L, Donos N, Tomás I. Accuracy of single molecular biomarkers in gingival crevicular fluid for the diagnosis of periodontitis: A systematic review and meta-analysis. Vol. 46, Journal of Clinical Periodontology. 2019. p. 1166–82.
72. Bapat RA, Pandurangappa R, Kumar Bhattamisra S, Heng YK, Matinlinna JP, Daood U. New perspective for probe development assessing salivary biomarkers in periodontal affected diabetic patients. Microchem J. 2021;170.
73. Wignarajah S, Suaifan GARY, Bizzarro S, Bikker FJ, Kaman WE, Zourob M. Colorimetric Assay for the Detection of Typical Biomarkers for Periodontitis Using a Magnetic Nanoparticle Biosensor. Anal Chem. 2015;87(24):12161–8.
74. Na HS, Kim SY, Han H, Kim HJ, Lee JY, Lee JH, et al. Identification of potential oral microbial biomarkers for the diagnosis of periodontitis. J Clin Med. 2020;9(5).
75. Zeidán-Chuliá F, Gürsoy M, de Oliveira BHN, Özdemir V, Könönen E, Gürsoy UK. A systems biology approach to reveal putative host-derived biomarkers of periodontitis by network topology characterization of MMP-REDOX/NO and apoptosis integrated pathways. Front Cell Infect Microbiol. 2016;5(JAN).
76. Dhir S, Bansal S, Wangnoo S, Jana DI. Periodontitis and diabetes mellitus—an awareness and perception study among endocrinologists and diabetologists. Int J Diabetes Dev Ctries. 2022;42(3):543–51.